IL6 and neoplasm: In the context of AR resistance, the PI3K/Akt/mTOR, MAPK, Wnt/β-catenin, and IL-6/JAK/STAT3 pathways sustain tumor cell survival and progression through multi-layered regulation, highlighting the importance of the cooperation among multiple pathways as new therapeutic targets for metastatic prostate cancer and resistance.